BKBill Kalionis

Bill Kalionis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bill Kalionis has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 205. Homeobox gene TGIF is increased in human idiopathic fetal growth restriction

    by P. Murthi, N. Pathirage, A. Borg, S. Brennecke, B. Kalionis

    Fetal Growth Restriction (FGR) is a clinically significant pregnancy disorder in which the fetus fails to achieve its full growth potential in utero. Recently, we identified a novel homeobox gene TGIF, in the placenta using microarray expression profiling (1). Targeted mutation of tgif in mouse results in placental dysfunction (2). In this study, we have investigated TGIF expression levels in idiopathic FGR. FGR-affected placental samples were collected based on strict clinical criteria to ensure inclusion of cases at the severe end of the spectrum of the disease. TGIF mRNA expression was analysed in placentae obtained from pregnancies complicated by idiopathic FGR and gestation-matched control pregnancies (n = 25 each). Real-time PCR showed a significant increase in TGIF mRNA levels in FGR-affected placentae and gestation-matched controls [1.29 ± 0.06 FGR v. 0.78 ± 0.04 Control, P < 0.001]. western blotting using a TGIF polyclonal antibody revealed significantly increased levels of TGIF protein in term FGR-affected placentae compared with term controls [3970 ± 1101 (n = 10) v. 2323 ± 644 (n = 10), P < 0.05]. The spatial distribution of TGIF protein by immunohistochemistry revealed immunoreactive TGIF protein in residual cytotrophoblast cells, syncytiotrophoblast cells, microvascular endothelial cells and in stromal cells. We conclude that increased expression of homeobox gene TGIF may be a contributing factor to the developmental abnormalities seen in the FGR-affected placentae. (1) Murthi P, Hiden U, Rajaraman G, Kalionis B. Placenta May 29, [Epub ahead of print]. (2) Bartholin L, Melhuish TA et al. Dev Biol. 2008 May 2. [Epub ahead of print].

  • 201. Homeobox gene DLX3 regulates forskolin induced trophoblast differentiation

    by A. Chui, B. Kalionis, S. Brennecke, P. Murthi

    Trophoblast cells carry out important functions required for the development of the normal placenta. Disruption of these functions is associated with significant pregnancy disorders such as fetal growth restriction and pre-eclampsia. Transcription factors regulate trophoblast functions. We are interested in one such class of transcription factors known as homeobox genes. The homeobox gene Distal-less 3 (DLX3) plays a vital role in the development of the mouse placenta (Morasso, Grinberg et al. 1999) and increased levels of DLX3 have been found in placentae affected by human fetal growth restriction (Murthi and Chui, unpubl. data). However, the function of DLX3 in the human placenta is not well established. Here, we investigated whether DLX3 regulates trophoblast differentiation using a plasmid construct to overexpress DLX3 in the human trophoblast cell line, BeWo. Real-time PCR showed a significant increase in DLX3 mRNA (3.1 ± 0.1 v. 1.0 ± 0.2 control, P < 0.05, n = 3), as well as the mRNA of two known markers of differentiation 3-β-hydroxysteroid dehydrogenase (3β-HSD) (8.1 ± 1.8 v. 1.2 ± 0.1 control, P < 0.05, n = 3) and β-human chorionic gonadotropin (β-hCG) (54.9 ± 0.9 v. 49.2 ± 1.6 control, P < 0.05, n = 3). Furthermore, forskolin mediated trophoblast differentiation was verified in BeWo cells. Following forskolin induction, real-time PCR showed a significant increase in the expression of DLX3 mRNA (12.9 ± 1.2 v. 3.8 ± 0.9 control, P < 0.05, n = 4), as well as a significant increase in the mRNA expression of the differentiation markers previously tested, 3β-HSD (28.3 ± 2.4 v. 1.0 ± 0.08 control, P < 0.05, n = 4) and β-hCG (2.3 ± 1.9 v. 30.9 ± 0.08 control, P < 0.001, n = 3). The expression of an additional differentiation marker, syncytin, was also significantly increased (4.0 ± 1.9 v. 1.0 ± 0.08 control, P < 0.05, n = 4). Thus, we have shown that DLX3 is a regulator of human trophoblast cell differentiation, and that forskolin acts through DLX3 to induce trophoblast differentiation. (1) Morasso, M. I., A. Grinberg et al. (1999).

  • 218. Homeobox gene HLX is expressed in choriodecidua mesenchymal stem cells and regulates their ability to migrate

    by S. Qin, P. Murthi, S. Brennecke, B. Kalionis

    Mesenchymal stem cells (MSCs) can be prepared from the placenta (PMSC) and the choriodecidua component of the fetal membranes (CDMSC). PMSCs and CDMSCs share basic stem cell properties with adult MSCs but differ in their gene expression profiles and ultrastructure, showing features of more primitive and metabolically quiescent stem cells (1). Homeobox gene transcription factors are critical markers for identifying stem cells and they regulate important stem cell functions. Our laboratory showed the homeobox gene HLX is expressed in the placenta and the choriodecidua component of the fetal membranes, and is a regulator of proliferation in placental cells (2). In this study, our aim was to determine whether HLX was expressed in CDMSCs and to use short interfering RNAs (siRNAs) to specifically inactivate HLX and determine the effect on CDMSC function. Complementary DNA was prepared from CDMSCs and RT–PCR using HLX-specific primers generated the expected band size of 485bp following agarose gel electrophoresis (n = 3). At the protein level, HLX expression was detected in the nuclei of CDMSCs using immunocytochemistry. The expected HLX protein product was detected at ~50kDa using western blotting (n = 3). Conditions were optimised for the use of short interfering RNAs (siRNA) to decrease HLX expression in CDMSCs with 5nM giving the most efficient downregulation. Two independent siRNAs were tested (HLXsi3–4) and of these, HLXsi4 resulted in significantly decreased HLX mRNA levels in CDMSCs as shown by real-time PCR (0.66 ± 0.08, P = 0.03, n = 3). Functional assays to measure stem cell migration were carried out in quadriplicates on two samples. 10000 cells were placed on one side of a filter and the number of cells that migrated to the other side of the filter was stained and densitometric analysis was carried out using Axiovision image analysis software. These results suggest that the HLXsi4-mediated decrease in HLX expression resulted in reduced CDMSC migration (2.6x103 ± 401 v. 1.3x103 ± 225 densitometric units, P = 0.02). Therefore, HLX may play a role in stem cell migration. (1) Pasquinelli G, Tazzari P, Ricci F, Vaselli C, Buzzi M, Conte R, Orrico C, Foroni L, Stella A, Alviano F, Bagnara GP and Lucarelli E., Ultrastructural characteristics of human mesenchymal stromal. (2) Rajaraman G, Murthi P, Quinn L, Brennecke SP, Kalionis B. Homeodomain protein HLX is expressed primarily in cytotrophoblast cell types in the early pregnancy human placenta. Reprod Fertil Dev. 2008. (3) Rajaraman G, Murthi P, Leo B, Brennecke SP and Kalionis B. Homeobox gene HLX1 is a regulator of colony stimulating factor-1 dependent trophoblast cell proliferation. Placenta. 2007. 28(10):991–8.

  • 220. Homeobox gene HLX is a regulator of HGF/c-met mediated trophoblast migration

    by G. Rajaraman, P. Murthi, S. P. Brennecke, B. Kalionis

    Homeobox gene transcription factors play critical roles in normal placental development and are expressed in specialised trophoblast cells. Abnormal trophoblast cell function is associated with pregnancy disorders including fetal growth restriction. Our studies show homeobox gene HLX expression in trophoblast cells (1) and that HLX is significantly decreased in fetal growth restriction (2). HLX gene inactivation in cultured trophoblast cells shows that HLX is a regulator of cytokine-dependent trophoblast proliferation (3). Hepatocyte growth factor (HGF) activates trophoblast cell migration in a paracrine fashion and its receptor, c-met, is expressed in trophoblast cells. This study investigates the regulation of HGF/c-met mediated trophoblast migration by HLX, in two human trophoblast cell lines SGHPL-4 and HTR-8/SVNeo. HGF stimulation significantly increased HLX mRNA expression (e.g. 43.2 ± 2.5, HGF v. 18.4 ± 1.7 control, densitometric units, P < 0.001, n = 3). siRNA-mediated inactivation of HLX resulted in significantly decreased trophoblast migration (e.g. 32 ± 4, siRNA v. 127 ± 12 control, migrated cells, P < 0.05, n = 4). When HLX was inactivated in the presence of HGF stimulation, migration remained significantly decreased (e.g. 112 ± 15, siRNA + HGF v. 368 ± 44 HGF, migrated cells, P < 0.05, n = 4). In order to determine if HGF is acting via the c-met receptor, the Met tyrosine kinase inhibitor, SU11274, was employed to inhibit c-met activity. c-met inhibition resulted in significantly reduced HLX mRNA expression (e.g. 2.1 ± 0.32, SU11274 v. 12.3 ± 1.4 control, densitometric units, P < 0.05, n = 3). HLX expression remained significantly reduced with HGF stimulation and SU11274 mediated c-met inhibition (e.g. 8.02 ± 1.3, SU11274 v. 38.3 ± 5.4 HGF, densitometric units, P < 0.05, n = 3). This is the first study to show that homeobox gene HLX is a downstream effector gene of HGF, that HLX regulates trophoblast migration and that HGF, via its receptor c-met, acts through HLX to control cell migration. (1) Rajaraman G, Murthi P, Quinn L, Brennecke SP, Kalionis B. Homeodomain protein HLX is expressed primarily in cytotrophoblast cell types in the early human placenta. (2008) Reproduction, Fertility a (2) Murthi P, Doherty V, Said J, Donath S, Brennecke SP, Kalionis B. Homeobox gene HLX1 expression is decreased in idiopathic human fetal growth restriction. (2006) Am J Pathol. 2006 Feb;168(2):511–8. (3) Rajaraman G, Murthi P, Leo B, Brennecke SP, Kalionis B. Homeobox gene HLX1 is a regulator of colony stimulating factor-1 dependent cell proliferation. (2007) Placenta Volume 28, Issue 10, October

  • Open Access

    Homeobox gene ESX1L expression is decreased in human pre-term idiopathic fetal growth restriction

    by Padma Murthi, Vicki L. Doherty, Joanne M. Said, Susan Donath, Shaun P. Brennecke, Bill Kalionis

    Fetal growth restriction (FGR) is a clinically significant pregnancy disorder in which the fetus fails to achieve its full growth potential in utero. This study involved idiopathic FGR, which is frequently associated with placental dysfunction. Here, we investigated mRNA levels of the human placental homeobox gene ESX1L in pre-term and term idiopathic FGR pregnancies compared with gestation-matched controls. Real-time PCR quantitation showed ESX1L levels in control placentae decreased between pre-term and term [0.7 ± 0.20 (27–35 weeks, n = 13) versus 0.2 ± 0.06 (36–41 weeks, n = 12), t-test, P < 0.005]. ESX1L levels in FGR-affected placentae were significantly lower than in gestation-matched controls, and there was no significant change between pre-term FGR and term FGR [0.32 ± 0.04 (27–36 weeks, n = 11) versus 0.31 ± 0.02 (36–41 weeks, n = 14), t-test, P = 0.82]. Multiple linear regression analysis revealed a rapid decline in ESX1L expression in control placentae [0.075-fold of the calibrator for each week of gestation (95% CI = –0.105 to –0.045, P < 0.0005)]. In FGR-affected placentae, ESX1L levels were lower than in gestation-matched controls, and the decline in ESX1L levels with gestation was not significant [0.001-fold of the calibrator for each week of gestation (95% CI = –0.030 to 0.010, P < 0.3]. The linear relationship between ESX1L mRNA levels in FGR-affected placentae and gestation-matched controls during gestation was significantly different (likelihood ratio test for interaction, P = 0.0005). Our findings were consistent with a potential role for the ESX1L gene within the growth control mechanism of the fetus, through its effect on placental function.